Researchers have created a groundbreaking antibody that combines targeting, delivery, and immune activation to treat cancer, ...

Researchers from the Walter and Eliza Hall Institute (WEHI)in Australia have found a new way to predict a subset of patients ...

News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

This industry symposium took place during the European Society for Medical Oncology (ESMO) Congress held in Barcelona, Spain, from 13 th –17 th September 2024. Schmid has received consulting fees from ...

for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) adjuvant therapy for patients with hormone receptor-positive/human epidermal ...

for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) adjuvant therapy for patients with hormone receptor-positive/human epidermal ...

Neoadjuvant and adjuvant therapy for early-stage breast cancer Research ... of adjuvant endocrine therapy are recommended to receive endocrine therapy alone or endocrine therapy plus targeted ...

One in eight women in the U.S. will be diagnosed with breast cancer at some point in their ... radiation and/or hormone therapy. Write down all of your questions and bring them to every doctor ...

It’s a call to action for all of us to raise awareness, prioritize early ... breast cancer. Diet is another key factor. Processed foods, unhealthy fats, and artificial chemicals can disrupt ...

“Importantly, the NCCN Guideline recommendation of ribociclib in this broad population reaffirms the importance of offering eligible patients with early breast cancer, including those with ...

Facing a breast cancer diagnosis, especially for women in their reproductive years, can feel like an overwhelming life shift. For those with hormone-positive breast cancer, this challenge becomes ...